Ligand Pharmaceuticals LGND reported its Q1 earnings results on Thursday, May 4, 2023 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Ligand Pharmaceuticals beat estimated earnings by 156.18%, reporting an EPS of $2.28 versus an estimate of $0.89.
Revenue was down $1.71 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.17 which was followed by a 4.12% increase in the share price the next day.
Here's a look at Ligand Pharmaceuticals's past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | 1.19 | 0.43 | 0.43 | 0.66 |
| EPS Actual | 1.36 | 1.31 | 1.03 | 0.76 |
| Revenue Estimate | 46.64M | 38.28M | 37.73M | 34.21M |
| Revenue Actual | 50.38M | 66.09M | 57.42M | 45.69M |
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | 1.19 | 0.43 | 0.43 | 0.66 |
| EPS Actual | 1.36 | 1.31 | 1.03 | 0.76 |
| Revenue Estimate | 46.64M | 38.28M | 37.73M | 34.21M |
| Revenue Actual | 50.38M | 66.09M | 57.42M | 45.69M |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Guidance
Ligand Pharmaceuticals management provided guidance for FY 2023, expecting earnings between $4.6 and $4.75 per share.
To track all earnings releases for Ligand Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.